News for KNSA Stock

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024 Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024 Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 Kiniksa Pharmaceuticals Provides Corporate Update Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023 Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023 Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023 Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023 Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022 Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022 Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022 Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022 Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021 Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference Kiniksa Announces Launch of ARCALYST Named Patient Program Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021 Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis Kiniksa Outlines Next Steps for the Development of Mavrilimumab Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404 Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404 Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020 Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at European Academy of Dermatology and Venereology Virtual Congress Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020 Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th Kiniksa Announces Upcoming Rilonacept Analyst Day Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020 Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020 Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY) Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference